Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: protein kinase inhibitors - Deciphera Pharmaceuticals

Next Previous
Drug Profile

Research programme: protein kinase inhibitors - Deciphera Pharmaceuticals

Alternative Names: DCC 2721; DCC-2157; DP-3407; DP-3429; DP-3556; DP-3590; DP-4178; DP-4610; DP-4904

Latest Information Update: 28 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Deciphera Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Bcr-Abl tyrosine kinase inhibitors; Colony stimulating factor inhibitors; Macrophage colony-stimulating factor receptor antagonists; Mitogen-activated protein kinase 14 inhibitors; Mitogen-activated protein kinase 3 inhibitors; P38 mitogen-activated protein kinase inhibitors; Platelet-derived growth factor alpha receptor antagonists; Platelet-derived growth factor receptor antagonists; Proto-oncogene protein b-raf inhibitors; Proto-oncogene protein c-akt inhibitors; Proto-oncogene protein c-kit inhibitors; Proto-oncogene protein c-met inhibitors; TIE-2 receptor antagonists; Vascular endothelial growth factor receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Gastrointestinal stromal tumours

Highest Development Phases

  • No development reported Cancer; Cancer metastases; Gastrointestinal stromal tumours; Solid tumours
  • Discontinued Autoimmune disorders; Inflammation; Rheumatoid arthritis

Most Recent Events

  • 28 Jan 2025 No recent reports of development identified for preclinical development in Cancer in USA
  • 11 Jun 2024 Deciphera Pharmaceuticals has been acquired by Ono Pharmaceutical
  • 03 Jan 2023 Protein kinase inhibitors are still in preclinical phase for cancer in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top